Vasculitis is a diverse disease with common clinical manifestations such as fibrinoid necrosis and blood vessel inflammation. The symptoms vary based on the size of the blood vessel. It is a potentially fatal condition, but if detected early and treated promptly, the one-year survival rate rises to about 90%. Giant cell arteritis and Takayasu arteritis are the most common types of large vessel vasculitis in Norway and Germany. Polyarteritis nodus is a type of medium artery Vasculitis Treatment Market that affects people of all ages, with HBV infection accounting for nearly half of all cases detected. Kawasaki illness is most common in children under the age of four, and it mostly affects the coronary artery. Antineutrophil cytoplasmic autoantibodies (ANCA) linked vasculitis, Churg-Strauss disease, and microscopic polyangiitis are all examples of small vessel vasculitis, which affects the small blood arteries that supply the kidneys and lungs.
Because of superior clinical outcomes in patients with ANCA-associated Vasculitis Treatment Market and prospective biological therapies in the pipeline with improved drug safety and efficacy, biologics are leading the drug class sector.
Due to an increase in the number of immunocompromised patients suffering from large vessel vasculitis and the rising prevalence of CD4 T cell-mediated Takayasu vasculitis in the Caucasian population, large vessel vasculitis dominated the illness type segment in 2017. Due to the increased incidence of ANCA-associated small vessel vasculitis in the Mongolian population and an increase in the occurrence of leukocytoclastic Vasculitis Treatment Market
with palpable purpura due to postviral syndromes and medications, small vessel vasculitis is expected to grow rapidly in the near future.
Important Developments
The approval and marketing of innovative therapies for the treatment of various forms of vasculitis is a top priority for the market's major players. For example, in July 2019, Pfizer Inc. announced that its RUXIENCE (rituximab-pvvr), a biosimilar to Rituxan (rituximab), was approved by the US Food and Drug Administration (FDA) for the treatment of adult patients with microscopic polyangiitis.
R&D initiatives linked to the treatment of Vasculitis Treatment Market
are being prioritised by major institutes and universities. For example, in August 2019, researchers from Hospital El Bierzo and Burgos University Hospital in Spain proposed that vasculitis be treated using disease management based on individual patient features and levels of illness severity.
0 Comments